Meeting
2023 ASCO Annual Meeting
Clinical utility of plasma ctDNA sequencing in metastatic urothelial carcinoma.
Authors
Clara Helal
Institut Gustave Roussy, Villejuif, France
Clara Helal , Cedric Pobel , Arnaud Bayle , Damien Vasseur , Claudio Nicotra , Felix Blanc-Durand , Natacha Naoun , Alice Bernard-Tessier , Anna Patrikidou , Emeline Colomba , Ronan Flippot , Alina Fuerea , Nathalie Auger , Maud Ngocamus , Benjamin Besse , Ludovic Lacroix , Etienne Rouleau , Santiago Ponce Aix , Antoine Italiano , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04932525
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4576)
DOI
10.1200/JCO.2023.41.16_suppl.4576
Abstract #
4576
Poster Bd #
68
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomas.
First Author: Julie Blanchi
Poster
2021 Genitourinary Cancers Symposium
Circulating tumor DNA analysis of genomic alterations in metastatic urothelial carcinoma from NCT03113266 study.
First Author: Haige Chen
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss